Insurers struggle with Sovaldi angst

Share this article:

Insurers are beginning to experience hepatitis-C-induced anxiety over Sovaldi. Forbes's Matthew Herper cites analyst research that indicates the high-priced drug could inflict earnings-per-share damage on payers of “as much as 10%.”

While Herper notes that analysts such as ISI Group's Mark Schoenebaum make the point that the virus-clearing drug may be cost-effective because it bypasses the high price of liver failure, Sovaldi's effectiveness and popularity could tax health systems more than anticipated because “insurers are always going to worry about patients coming out of the woodwork.”

Herper's example: heartburn, “which was treated far less often before AstraZeneca launched Prilosec, which was very effective and became the best-selling drug in the world.”

Lawmakers and others have attacked the drug's high price, around $84,000 for 12 weeks of treatment. Earlier regimens, such as direct-acting antiviral treatments like Merck's Victrelis and Vertex's Incivek, cost between $80,000 and $100,000 for the duration of treatment.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.